How OPSYNVI® Works to Help You Take on PAH
OPSYNVI® is a once-daily approach to two foundational pathways—helping you treat PAH by targeting the nitric oxide and endothelin pathways.
Active Ingredients
OPSYNVI® is a medicine that contains 2 medicines called macitentan and tadalafil and is used for long-term treatment of adults with pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs.
About Macitentan
Individually, macitentan is an ERA that reduces the risk of clinical worsening events (a decline in 6-minute walk distance, worsening of PAH symptoms, and need for additional PAH treatment) and hospitalization for PAH.
ERA=endothelin receptor antagonist
About Tadalafil
Individually, tadalafil is a PDE5i that improves exercise ability.
PDE5i=phosphodiesterase type 5 inhibitor
Review the Medication Guide for a complete list of ingredients in OPSYNVI®.
Combination therapy with macitentan and tadalafil is a clinical guideline* recommendation for PAH treatment.
Clinical guidelines are evidence-based recommendations that assist healthcare providers in diagnosing and treating a medical condition.
Dual combination treatment with macitentan and tadalafil, is a guideline recommendation for the initial treatment of pulmonary arterial hypertension (PAH) for patients with certain types of PAH† who do not have other conditions of the heart and lungs.
*2022 European Society of Cardiology/European Respiratory Society Guidelines.
†Cause unknown (idiopathic), heritable, drug-related PAH, or PAH linked to connective tissue disease.
Stay in the Know With OPSYNVI®
Exciting updates are underway! Sign up for exclusive updates on OPSYNVI®.
Sign Up
